TTY Biopharm Company (4105) Stock Overview

TTY Biopharm Company Limited, together with its subsidiaries, engages in the development and sale of pharmaceutical and chemical drugs in Taiwan and internationally. The company operates through Oncology Business Unit, Health Care Unit, Anti-infection Business Unit, Domestic Cardiovascular and Gastrointestinal Drugs Business Unit, China Medicine Business Unit, and Other segments. It offers oncology drugs under the Lipo-Dox, Lonsurf, UFUR, TS-1, Pexeda, Gemmis, Oxalip, Irino, Epicin, Tynen, Anazo, Folina, Thado, Andason, Ivic, Asadin, Leavdo, Painkyl, Megest, Episil, Otril, Zobonic, Yondelis, and Pemazyre names for anti-cancer and supplementary treatments. The company also provides anti-infection drugs under the Brosym, Colimycin, Cubicin, Lipo-AB, Agrippal, Cepiro, Flusine, Maxtam, Metacin, and Flucelvax names for anti-infection and flu. In addition, it offers healthcare related drugs under the Algitab, Alginos, Alginos Fresh, Bio-Cal Plus, and Sulfin names for digest system, osteoporosis, and metabolism. Further, the company engages in the selling functional foods; and import and export trading and investment activities. TTY Biopharm Company Limited was incorporated in 1960 and is headquartered in Taipei, Taiwan.